Xtant Medical Announces Commercial Launch of its Next-Generation nanOss Strata™ Synthetic Bone Graft

Rhea-AI Summary

Xtant Medical (NYSE American: XTNT) announced the commercial launch on December 11, 2025 of its next‑generation synthetic bone graft, nanOss Strata.

nanOss Strata is made from hydroxycarbonapatite (HCA), a more soluble material than traditional hydroxyapatite, and uses a nanocrystalline structure to more closely mimic human bone, increase surface area, improve osteoconductivity, and enhance cellular stimulation for integration and remodeling. Strata is offered as compression‑resistant preformed strips and prehydrated moldable grafts, both sterile, highly moldable, and designed to rapidly absorb blood and biologic fluids. The product is available through Xtant Medical's nationwide distribution network.

News Market Reaction

-1.08%

4 alerts

-1.08% News Effect

+7.7% Peak Tracked

-$1M Valuation Impact

$114M Market Cap

0.1x Rel. Volume

On the day this news was published, XTNT declined 1.08%, reflecting a mild negative market reaction. Argus tracked a peak move of +7.7% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $114M at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Reality Check

Price: $0.5983 Vol: Volume 140,109 is below t...

normal vol

$0.5983 Last Close

Volume Volume 140,109 is below the 20-day average of 181,983 (relative volume 0.77x). normal

Technical Price 0.7025 is trading above the 200-day MA at 0.62 but is 26.05% below the 52-week high.

Peers on Argus

XTNT was down 5.07% pre-news while key peers showed mixed moves: APYX -1.47%, TE...

1 Up

XTNT was down 5.07% pre-news while key peers showed mixed moves: APYX -1.47%, TELA -0.85%, BDMD -10.13%, but LUNG +6.96% and NSPR +4.42%. This pattern points to stock-specific rather than sector-wide pressure.

Historical Context

5 past events · Latest: Dec 01 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 01	Asset divestiture	Neutral	+0.0%	Completion of Paradigm Spine asset sale to Companion Spine with minimal price move.
Dec 01	Asset sale	Positive	+0.0%	Sale of Coflex assets and Paradigm OUS entities for about $19.2M consideration.
Nov 10	Earnings release	Positive	+1.1%	Strong Q3 2025 revenue growth and margin expansion with positive earnings.
Nov 05	Product launch	Positive	+7.5%	Commercial launch of CollagenX bovine collagen wound-closure product.
Nov 04	Earnings notice	Neutral	-8.6%	Scheduling announcement for Q3 2025 results followed by an 8.55% price drop.

Pattern Detected

Recent news catalysts, especially product launches and solid earnings, have generally aligned with modestly positive price reactions, with only one notable divergence on an earnings-related announcement.

Recent Company History

Over the last few months, Xtant Medical reported several meaningful developments. On Nov 4–5, 2025, it announced Q3 results and launched CollagenX™, with the launch drawing a 7.55% gain. Q3 2025 earnings on Nov 10 showed revenue of $33.3M and improved margins, followed by balanced trading. On Dec 1, 2025, Xtant completed divestitures of Coflex assets and Paradigm OUS businesses, with minimal price impact. Today’s nanOss Strata™ launch continues the recent theme of expanding its biologics and regenerative solutions portfolio.

Market Pulse Summary

This announcement highlights the commercial launch of nanOss Strata™, a next‑generation synthetic bo...

Analysis

This announcement highlights the commercial launch of nanOss Strata™, a next‑generation synthetic bone graft designed to mimic human bone and improve osteoconductivity and cellular activity. It follows a series of developments, including CollagenX™ introduction and recent asset divestitures completed on Dec 1, 2025. Investors may focus on adoption through Xtant’s nationwide distribution network, how Strata complements the broader biologics portfolio, and upcoming financial updates to gauge the product’s contribution to growth.

Key Terms

hydroxycarbonapatite, hydroxyapatite, osteoconductivity, nanocrystalline, +4 more

8 terms

hydroxycarbonapatite medical

"nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material..."

Hydroxycarbonapatite is a bone-like mineral used in medical and dental products to help bone and tooth tissue attach and grow; think of it as a scaffold that encourages the body to rebuild hard tissue. It matters to investors because products and implants that use this material can affect sales, regulatory approval paths, and reimbursement decisions in the orthopedic and dental markets, so demand, manufacturing quality, and clinical data can directly influence a company’s financial prospects.

hydroxyapatite medical

"higher solubility than traditional hydroxyapatite (HA), the most commonly used synthetic material."

A naturally occurring mineral made of calcium and phosphate that forms the hard part of bone and teeth; in medicine it’s used as a powder, coating or scaffold to help new bone grow and to improve how implants bond with the body. Investors watch hydroxyapatite because products that use it can reduce recovery time, lower complication rates and differentiate medical devices or dental supplies, affecting sales, regulatory approval chances and long-term treatment costs.

osteoconductivity medical

"increase the surface area for improved osteoconductivity and stimulation of the patient's cellular activity"

Osteoconductivity is a material property that lets new bone grow along and into a medical implant or graft by acting like a scaffold or trellis for bone-forming cells. For investors, higher osteoconductivity can mean better healing outcomes, fewer repeat surgeries, and stronger clinical and regulatory cases for products used in orthopedics and dental implants—factors that influence market adoption, pricing power, and long-term sales potential.

nanocrystalline medical

"The nanocrystalline structure of HCA used in the nanOss Strata is designed..."

Nanocrystalline describes a material made up of extremely tiny crystals or grains measured in nanometers — a billionth of a meter — so the solid behaves more like a very fine powder than a chunk of rock. That microscopic structure can change strength, electrical or thermal behavior, chemical reactivity and how a material is made or regulated, so investors watch for it as a potential source of better product performance, lower costs, safety considerations, patents and market advantage.

regenerative medicine medical

"Strata further demonstrates our commitment to innovation in regenerative medicine."

A field of medical treatments that aims to repair, replace or regenerate damaged tissues and organs using approaches such as cell or gene therapies, engineered tissues, and biologically active materials. It matters to investors because successful regenerative therapies can create entirely new, high-value markets and replace chronic treatments, offering large potential returns but also long development timelines, heavy regulation and high technical risk—like betting on a promising new technology that could either revolutionize care or fail in trials.

synthetic bone graft medical

"commercial launch of its next-generation innovative synthetic bone graft in the nanOss line"

A synthetic bone graft is a lab-made material used to replace or support missing bone by acting like a scaffold that new bone can grow into, similar to putting a trellis under a climbing plant. For investors, it matters because its safety, effectiveness, manufacturing cost, and regulatory approval drive adoption by surgeons, reimbursement by insurers, and sales growth in the orthopedics and dental markets.

prehydrated medical

"available in compression-resistant preformed strips and prehydrated moldable grafts."

A product or material that has been hydrated — meaning water has already been added — before it reaches the end user, such as a powder, gel or device supplied in a ready-to-use, water-containing form. For investors this matters because prehydration can change manufacturing steps, storage needs, shelf life, regulatory testing and user convenience, all of which affect costs, pricing and how quickly a product can be adopted in the market (think instant soup versus dry mix that needs boiling water).

distribution network technical

"nanOss Strata is now accessible through Xtant Medical's nationwide distribution network."

A distribution network is the system of warehouses, transportation, retail or online partners and processes a company uses to get its products or services from where they are made to the customer’s hands. Investors care because the efficiency and reliability of that network directly affect sales, costs and customer satisfaction—like a building’s plumbing, a well-designed network delivers value smoothly while problems can lead to lost revenue and higher expenses.

AI-generated analysis. Not financial advice.

nanOss Strata™ is designed to more closely mimic the structure of human bone, increase the graft's surface area, improve osteoconductivity and enhance the stimulation of cellular activity

BELGRADE, Mont., Dec. 11, 2025 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, today announced the commercial launch of its next-generation innovative synthetic bone graft in the nanOss line, Strata™.

nanOss Strata is manufactured from hydroxycarbonapatite (HCA), a material with higher solubility than traditional hydroxyapatite (HA), the most commonly used synthetic material. Increased solubility can enhance the bioactivity of the graft, which allows for better integration and remodeling with the surrounding bone tissue during the healing process. The nanocrystalline structure of HCA used in the nanOss Strata is designed to closely mimic human bone and increase the surface area for improved osteoconductivity and stimulation of the patient's cellular activity on the surface of the graft after implantation. 

Strata is available in compression-resistant preformed strips and prehydrated moldable grafts. Both options are sterile, highly moldable, and quickly absorb blood and other biologic fluids. 

Sean Browne, President and CEO of Xtant Medical, stated, "By building on the clinical success of our nanOss products, Strata further demonstrates our commitment to innovation in regenerative medicine. We are excited to introduce this new technology to help our surgeon customers improve the surgical outcomes of their patients."

nanOss Strata is now accessible through Xtant Medical's nationwide distribution network.

About Xtant Medical Holdings, Inc.

Xtant Medical's mission of honoring the gift of donation so that our patients can live as full and complete a life as possible, is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics serving the chronic and surgical wound care and sports medicine markets, as well as spinal implant systems. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.

The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in the United States, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that contain words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's expectations regarding the benefits and performance of nanOss Strata™ and its potential to improve outcomes for patients utilizing nanOss Strata™. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability of nanOss Strata™ and other new products to gain market acceptance, perform as designed and intended, and meet the needs of surgeons and patients; the ability of the Company and its sales personnel and distributors to successfully sell nanOss Strata™; the Company's ability to successfully manufacture nanOss Strata™ and in amounts required to meet demand; the Company's ability to continue to innovate, develop and introduce new products and the success of those products; the performance and success of the Company's fully vertically integrated structure; the Company's ability to engage and retain new and existing independent distributors, agents and qualified personnel and its dependence on key independent agents for a significant portion of its revenue; the Company's future operating and financial performance and its ability to increase or maintain revenue; and other risk factors, including in particular those associated with the launch of new products, contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 6, 2025 and subsequent SEC filings by the Company, including without limitation its most recent Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 filed with the SEC on November 10, 2025. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-announces-commercial-launch-of-its-next-generation-nanoss-strata-synthetic-bone-graft-302638414.html

SOURCE Xtant Medical Holdings, Inc.

FAQ

What is nanOss Strata and when did Xtant Medical (XTNT) launch it?

nanOss Strata is a next‑generation synthetic bone graft made from hydroxycarbonapatite (HCA), commercially launched on December 11, 2025.

How does nanOss Strata (XTNT) differ from traditional synthetic bone grafts?

Strata uses HCA with a nanocrystalline structure that is more soluble than traditional HA and is designed to increase surface area, osteoconductivity, and cellular stimulation.

What product formats does Xtant Medical (XTNT) offer for nanOss Strata?

Strata is available as compression‑resistant preformed strips and prehydrated moldable grafts, both sterile and highly moldable.

How is nanOss Strata intended to aid bone healing according to Xtant (XTNT)?

Increased solubility and nanocrystalline structure are intended to enhance bioactivity, integration, remodeling, and stimulation of the patient's cellular activity during healing.

Is nanOss Strata available to surgeons nationwide from Xtant Medical (XTNT)?

Yes. nanOss Strata is accessible through Xtant Medical's nationwide distribution network.

Does the nanOss Strata announcement for XTNT include specific clinical or financial results?

No. The announcement describes product design and availability but does not provide specific clinical data or financial figures.